Glycopeptide derivatives.

Area of Science:

• Microbiology
• Medicinal Chemistry
• Pharmacology

Background:

• Increasing resistance to glycopeptide antibiotics (e.g., vancomycin) in enterococci and Staphylococcus aureus poses a significant clinical challenge.
• The emergence of VanA strains and vancomycin-intermediate Staphylococcus aureus (GISA) necessitates the development of novel therapeutic agents.
• Existing treatment options are limited, particularly for infections caused by multidrug-resistant Gram-positive bacteria.

Purpose of the Study:

• To review the development of second-generation glycopeptides with enhanced activity against resistant bacteria.
• To discuss novel chemical modifications aimed at overcoming glycopeptide resistance mechanisms.
• To highlight compounds currently in clinical trials for treating resistant infections.

Main Methods:

• Chemical modification of existing glycopeptide structures (vancomycin, teicoplanin).
• Development of second-generation compounds like LY333328 and BI 397.
• Exploration of modifications to the heptapeptide core and sugar moieties.
• Synthesis of glycopeptide dimers and vancomycin derivatives.

Main Results:

• Second-generation glycopeptides LY333328 and BI 397 demonstrate promising activity against VanA enterococci, GISA, and penicillin-resistant pneumococci.
• Chemical modifications targeting the heptapeptide core and D-Ala-D-Ala/D-Ala-D-Lactate binding interactions show potential.
• Ongoing clinical trials are evaluating the efficacy and safety of these novel glycopeptides.

Conclusions:

• There is an urgent need for new glycopeptides to address the growing threat of antibiotic resistance.
• Chemical innovation in glycopeptide structure is yielding promising drug candidates.
• Further research and clinical evaluation are crucial for the successful deployment of these next-generation antibiotics.